Centre Regional Lutte Contre Le Cancer

At the Centre Regional Lutte Contre Le Cancer in Strasbourg, the strongest focus is on neoplasms, with many studies exploring how to improve treatment for a wide range of cancers in the Medical Oncology setting. Research is centered on testing new therapies, refining treatment combinations, and comparing approaches to help control disease and extend survival.

• Breast cancer, including HER2-positive, HER2-negative, triple-negative, and hormone receptor-positive disease
• Gastrointestinal cancers such as gastric, colorectal, biliary tract, rectal, and gastroesophageal junction cancers
• Head and neck cancers, including recurrent and metastatic squamous cell carcinoma

These trials commonly aim to improve disease control, reduce relapse risk, and identify better options for patients with advanced or high-risk cancers.

Breast cancer is a major research area at this site, covering early, locally advanced, metastatic, and treatment-resistant disease. Studies are evaluating new targeted and immunotherapy-based strategies, while others are looking at ways to safely reduce treatment intensity for patients who respond well.

• HER2-positive and HER2-amplified breast cancer
• HER2-negative and hormone receptor-positive breast cancer
• Triple-negative and metastatic breast cancer

Overall, the goal is to improve long-term outcomes, personalize care, and find more tolerable treatment paths for people living with breast cancer.

Another important theme is digestive system diseases, especially cancers of the stomach, colon, rectum, biliary tract, and gastroesophageal junction. The trials are designed to test new treatment combinations, strengthen postoperative strategies, and improve outcomes in advanced or unresectable disease.

• Gastric and gastroesophageal junction adenocarcinoma
• Colorectal and rectal cancer
• Biliary tract cancer and cholangiocarcinoma

Research here is focused on extending survival, lowering recurrence rates, and improving disease control when standard treatment is not enough.

The site also has a strong program in male urogenital diseases, especially advanced prostate cancer. Several studies are evaluating new radioligand, hormonal, and imaging-guided approaches to better manage metastatic disease and identify patients at higher risk of relapse.

• Metastatic castration-resistant prostate cancer
• Metastatic hormone-sensitive prostate cancer
• Localized high-risk prostate cancer with advanced imaging assessment

These trials aim to improve survival, refine treatment selection, and support more precise care through modern diagnostic tools.

Research in respiratory tract diseases and nervous system diseases includes aggressive cancers such as non-small cell lung cancer, large-cell neuroendocrine carcinoma, glioblastoma, and low-grade glioma. The studies are testing new systemic therapies, better imaging methods, and approaches to improve control of difficult-to-treat brain and lung tumors.

• Non-small cell lung cancer and large-cell neuroendocrine carcinoma
• Glioblastoma and low-grade glioma
• Brain metastases and brain radionecrosis after radiotherapy

Work in this area is aimed at improving diagnosis, managing treatment-related complications, and finding more effective options for advanced disease.

Beyond direct cancer treatment, the site is also studying pathological conditions, signs and symptoms linked to cancer and its therapies. This includes research on neuropathy, cachexia, vasomotor symptoms, and other quality-of-life issues that can affect patients during or after treatment.

• Chemotherapy-induced peripheral neuropathy
• Cancer-associated cachexia
• Hot flashes and other endocrine therapy-related symptoms

These trials focus on easing symptoms, improving daily functioning, and making cancer care more manageable for patients.

In addition to therapeutic studies, the Analytical, Diagnostic and Therapeutic Techniques and Equipment field is represented through research that improves how cancers are detected, characterized, and monitored. This includes imaging-based assessment, biomarker-driven selection, and studies using molecular information to guide treatment decisions.

• Advanced imaging for glioma characterization and prostate cancer detection
• ctDNA-guided treatment strategies in selected cancers
• Biomarker-focused studies in breast, gastric, and colorectal cancer

These efforts are intended to make diagnosis more accurate and help match patients with the most appropriate treatment.